Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28834183 | 0.98 | DPP4 (0.48) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL28056504 | 0.95 | DPP4 (0.46) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL21986229 | 0.87 | DPP4 (0.43) | DPP4PREP | |
| SCHEMBL499973 | 0.82 | S1PR1 (0.47) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL499972 | 0.82 | S1PR1 (0.47) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660886 | 0.81 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660792 | 0.81 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660557 | 0.81 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660224 | 0.81 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9661749 | 0.81 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814599-A4 | COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 | BIOREXIS PHARMACEUTICAL CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1864137-A2 | METHODS TO IDENTIFY AND CHARACTERIZE PROLYL OLIGO-PEPTIDASES BY USING SUBSTRATES AND PRODUCTS THEREOF | DIGILAB BioVisioN GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1814599-A2 | COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 | Biorexis Pharmaceutical Corporation (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1741790-A1 | Methods to identify and characterize prolyl oligopeptidases by using substrates and products thereof | DIGILAB BioVisioN GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006100096-A2 | METHODS TO IDENTIFY AND CHARACTERIZE PROLYL OLIGO-PEPTIDASES BY USING SUBSTRATES AND PRODUCTS THEREOF | DIGILAB BIOVISION GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006017688-A2 | COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2006-02-16 | — | — | WO | disclosed |
| US-6617340-B1 | Treating non-insulin-dependent diabetes mellitus | NOVARTIS AG (CH) | 2003-09-09 | — | — | US | disclosed |
| US-6110949-A | A SERINE PROTEASE INHIBITOR TREATING NON-INSULIN-DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-08-29 | — | — | US | disclosed |
| US-6107317-A | ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2000-08-22 | — | — | US | disclosed |